Literature DB >> 24962329

Neurofunctional changes in adolescent cannabis users with and without bipolar disorder.

Samantha M Bitter1, Caleb M Adler, James C Eliassen, Wade A Weber, Jeffrey A Welge, Joaquin Burciaga, Paula K Shear, Stephen M Strakowski, Melissa P DelBello.   

Abstract

AIMS: To compare regional brain activation among adolescents with bipolar disorder and co-occurring cannabis use disorder.
DESIGN: Cross-sectional study.
SETTING: Cincinnati, OH, USA. PARTICIPANTS: Adolescents with bipolar disorder (BP, n = 14), adolescents with cannabis use disorder (MJ, n = 13), adolescents with co-occurring cannabis use and bipolar disorders (BPMJ, n = 25) and healthy adolescents (HC, n = 15). MEASUREMENTS: Cannabis craving, substance use, Blood Oxygenation Level Dependent (BOLD) signal assessed by the Marijuana Craving Questionnaire (MCQ), Teen-Addiction Severity Index (T-ASI) and a cannabis cue-reactivity task during a functional magnetic resonance imaging (fMRI) session, respectively.
FINDINGS: The BP group exhibited significantly greater brain activation than the BPMJ group in the right amygdala (F = 4.14, P = 0.046), left nucleus accumbens (F = 3.8, P = 0.02), left thalamus (F = 3.8, P < 0.05) and the right thalamus (F = 6.2, P = 0.02). The BP group exhibited significantly greater activation than the HC group in the left nucleus accumbens (F = 11.5, P = 0.0001), right thalamus (F = 4.9, P = 0.03) and the left striatum (F = 3.6, P = 0.04). Left amygdala activation of the BPMJ group trended towards being significantly negatively correlated with the number of joints smoked (R = -0.4, P = 0.06).
CONCLUSIONS: Bipolar adolescents with comorbid cannabis use do not exhibit the same over-activation of the regions involved in emotional processing as seen in adolescents with bipolar disorder alone. The absence of these findings in patients with comorbid bipolar and cannabis use disorders suggests that these individuals may have a unique endophenotype of bipolar disorder or that cannabis use may alter brain activation uniquely in bipolar disorder patients who use cannabis.
© 2014 Society for the Study of Addiction.

Entities:  

Keywords:  Adolescent; bipolar disorder; cannabis; fMRI; functional magnetic resonance imaging; marijuana

Mesh:

Year:  2014        PMID: 24962329     DOI: 10.1111/add.12668

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  5 in total

1.  Brain circuitry associated with the development of substance use in bipolar disorder and preliminary evidence for sexual dimorphism in adolescents.

Authors:  Elizabeth T C Lippard; Carolyn M Mazure; Jennifer A Y Johnston; Linda Spencer; Judah Weathers; Brian Pittman; Fei Wang; Hilary P Blumberg
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

Review 2.  Associations between cannabis use, cannabis use disorder, and mood disorders: longitudinal, genetic, and neurocognitive evidence.

Authors:  Lauren Kuhns; Emese Kroon; Karis Colyer-Patel; Janna Cousijn
Journal:  Psychopharmacology (Berl)       Date:  2021-11-06       Impact factor: 4.415

3.  Higher Prevalence of Metabolic Syndrome in Child-adolescent Patients with Bipolar Disorder.

Authors:  Satyajit Mohite; Hanjing Wu; Shiva Sharma; Luca Lavagnino; Cristian P Zeni; Terrence T Currie; Jair C Soares; Teresa A Pigott
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-05-31       Impact factor: 2.582

4.  Cannabis use and resting state functional connectivity in adolescent bipolar disorder.

Authors:  Alysha A Sultan; Megan A Hird; Mikaela K Dimick; Bradley J MacIntosh; Benjamin I Goldstein
Journal:  J Psychiatry Neurosci       Date:  2021-09       Impact factor: 6.186

Review 5.  Patterns of brain function associated with cannabis cue-reactivity in regular cannabis users: a systematic review of fMRI studies.

Authors:  Hannah Sehl; Gill Terrett; Lisa-Marie Greenwood; Magdalena Kowalczyk; Hannah Thomson; Govinda Poudel; Victoria Manning; Valentina Lorenzetti
Journal:  Psychopharmacology (Berl)       Date:  2021-09-10       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.